Buscar
Matinas BioPharma Holdings Inc
MTNBAñadir a la lista de seguimiento
0.290USD
-0.027-8.57%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.71MCap. mercado
PérdidaP/E TTM
Más Datos de Matinas BioPharma Holdings Inc Compañía
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Información de Matinas BioPharma Holdings Inc
Símbolo de cotizaciónMTNB
Nombre de la empresaMatinas BioPharma Holdings Inc
Fecha de salida a bolsaJun 03, 2014
Director ejecutivoJabbour (Jerome D)
Número de empleados3
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 03
DirecciónSuite 302
CiudadBEDMINSTER
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal07921
Teléfono19084431860
Sitio Webhttps://www.matinasbiopharma.com/
Símbolo de cotizaciónMTNB
Fecha de salida a bolsaJun 03, 2014
Director ejecutivoJabbour (Jerome D)
Ejecutivos de Matinas BioPharma Holdings Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Matinas BioPharma Holdings Inc?
Los cinco principales accionistas de Matinas BioPharma Holdings Inc son: Mr. Jerome D. Jabbour, J.D.
¿Cuántas instituciones poseen acciones de Matinas BioPharma Holdings Inc (MTNB)?
A fecha de 2026Q1, 81 instituciones poseen acciones de Matinas BioPharma Holdings Inc, con un valor de mercado combinado de aproximadamente 511.24K, lo que representa el 7.98% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -956971.00.